Haleon Pakistan Limited has approved an investment of USD 4.9 million to expand and modernise its Panadol Liquid packaging line, as part of efforts to boost production capacity and improve operational efficiency amid rising demand. the company,  formerly known as GlaxoSmithKline,    disclosed the development in a notice to the Pakistan Stock Exchange.         The investment and associated financing have been approved by the Board of Directors of Haleon Pakistan Limited, and will include the procurement of advanced packaging machinery, upgrades to existing infrastructure, and implementation of quality control enhancements.      Haleon Pakistan Limited was incorporated in Pakistan as a public limited company in 2015. The principal activity of the company is the manufacturing, marketing, and sale of consumer healthcare and over-the-counter health products.   The company is a subsidiary of “Haleon Netherlands B.V.’ while Haleon plc is the ultimate parent company. (ICE ISLAMABAD)

Fonte notizia: business recorder